Simon Kornvig, Henrik Kehlet, Christoffer Calov Jørgensen, Anders Fink-Jensen, Poul Videbech, Martin Lindberg-Larsen, Kirill Gromov, Mathias Bæk Rasmussen, Manuel Josef Bieder, Claus Varnum
Psychopharmacological treatment may be an independent risk factor for increased length of stay and readmission after hip and knee replacement. Thus, temporary perioperative discontinuation may be beneficial. However, little is known regarding the treatments, and not all are feasible to discontinue. Therefore, the aim of this study was to describe the treatments in terms of type, dose, duration, indication and initiating physician to assess the feasibility of temporary perioperative discontinuation. We included 482 patients planned for hip or knee replacement in psychopharmacological treatment for psychiatric disorders from 2021 to 2023 at five orthopaedic departments in Denmark...
May 10, 2024: Basic & Clinical Pharmacology & Toxicology